Multiple endocrine neoplasia type 2: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
{{SK}} Multiple endocrine adenomatosis, type 2, Multiple endocrine neoplasia syndrome type 2, MEN, type 2, MEN 2 syndrome, MEN 2 - Multiple endocrine neoplasia syndrome type 2, MEN type II, | {{SK}} Adenomatosis, familial endocrine type 2, Endocrine neoplasia, multiple type 2, Familial endocrine adenomatosis type 2, Familial chromaffinomatosis type 2, Familial medullary thyroid carcinoma, Multiple endocrine adenomatosis, type 2, Multiple endocrine neoplasia syndrome type 2, MEN, type 2, MEN 2 syndrome, MEN 2 - Multiple endocrine neoplasia syndrome type 2, MEN type II, MEA type 2, MEN type 2, Multiple endocrine adenomatosis type 2, Multiple endocrine neoplasms type 2, MEA 2a, MEA II, MEA IIa, MEN 2, MEN 2a, MEN 2b, MEN IIa, MEN IIb, MEN2a, MEN2b, Multiple Endocrine Neoplasms Type 2a, Multiple Endocrine Neoplasms Type 2b, Multiple neuroma syndrome type 2, Multiple neuroma syndrome type 2a, Multiple neuroma syndrome type 2b, Neoplasia, Multiple Endocrine Type 2a, Neoplasia, Multiple Endocrine Type 2b, Neoplasms, Multiple Endocrine Type 2a, Neoplasms, Multiple Endocrine Type 2b, PTC syndrome, Sipple's syndrome, Pheochromocytoma and amyloid producing medullary thyroid carcinoma, Wagenmann-Froboese syndrome | ||
==[[Multiple endocrine neoplasia type 2 overview|Overview]]== | ==[[Multiple endocrine neoplasia type 2 overview|Overview]]== | ||
Revision as of 14:12, 27 September 2015
|
Multiple endocrine neoplasia type 2 Microchapters |
|
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Multiple endocrine neoplasia type 2 On the Web |
|
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 |
|
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
|
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Synonyms and keywords: Adenomatosis, familial endocrine type 2, Endocrine neoplasia, multiple type 2, Familial endocrine adenomatosis type 2, Familial chromaffinomatosis type 2, Familial medullary thyroid carcinoma, Multiple endocrine adenomatosis, type 2, Multiple endocrine neoplasia syndrome type 2, MEN, type 2, MEN 2 syndrome, MEN 2 - Multiple endocrine neoplasia syndrome type 2, MEN type II, MEA type 2, MEN type 2, Multiple endocrine adenomatosis type 2, Multiple endocrine neoplasms type 2, MEA 2a, MEA II, MEA IIa, MEN 2, MEN 2a, MEN 2b, MEN IIa, MEN IIb, MEN2a, MEN2b, Multiple Endocrine Neoplasms Type 2a, Multiple Endocrine Neoplasms Type 2b, Multiple neuroma syndrome type 2, Multiple neuroma syndrome type 2a, Multiple neuroma syndrome type 2b, Neoplasia, Multiple Endocrine Type 2a, Neoplasia, Multiple Endocrine Type 2b, Neoplasms, Multiple Endocrine Type 2a, Neoplasms, Multiple Endocrine Type 2b, PTC syndrome, Sipple's syndrome, Pheochromocytoma and amyloid producing medullary thyroid carcinoma, Wagenmann-Froboese syndrome
Overview
Historical Perspective
Classification
Pathophysiology
Epidemiology & Demographics
Risk Factors
Screening
Causes of Multiple endocrine neoplasia type 2
Differentiating Multiple endocrine neoplasia type 2 from other Diseases
Natural History, Complications & Prognosis
Classification
Diagnosis
History & Symptoms | Physical Examination | Lab Tests | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
See also
References
This article incorporates public domain text from The U.S. National Library of Medicine